Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - DENDREON CORPexhibit_99-1.htm


SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
 
 
FORM 8-K
________________
 
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 7, 2011
________________
 
 
DENDREON CORPORATION
(Exact name of registrant as specified in its charter)
________________
 
Delaware
000-30681
22-3203193
(State or other jurisdiction
(Commission File Number)
(I.R.S. Employer
of incorporation)
 
Identification Number)

 
3005 First Avenue
Seattle, Washington
98121
(Address of principal executive offices) (zip code)
 
(206) 256-4545
(Registrant’s telephone number, including area code)
 
None
(Former name or former address, if changed since last report)
________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£           Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

£           Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

£           Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

£           Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

Item 8.01. Other Events.
 
On January 7, 2011, Dendreon Corporation (the “Company”) announced its plans to seek marketing authorization for PROVENGE® (sipuleucel-T) in Europe, several updates regarding the U.S. commercialization of PROVENGE, and the Company’s progress on its pipeline.  See attached Exhibit 99.1 for the full text of the press release.
 
Item 9.01. Financial Statements and Exhibits.

(d)      Exhibits

 
99.1
Dendreon Corporation press release dated January 7, 2011.
 
 
2

 


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
  DENDREON CORPORATION  
       
 
By:
/s/ Richard F. Hamm, Jr.  
    Richard F. Hamm, Jr.  
    Executive Vice President, General Counsel and Secretary  
January 7, 2011      

 
3

 

 
EXHIBIT INDEX
 
Exhibit No.
 
 
Description                                                                                           
  99.1  
Dendreon Corporation press release dated January 7, 2011.
       
 
 
4